Literature DB >> 23016549

Anticholinergic effects of oral antipsychotic drugs of typicals versus atypicals over medium- and long-term: systematic review and meta-analysis.

M Ozbilen1, C E Adams, J Marley.   

Abstract

BACKGROUND: Anticholinergic side-effects of antipsychotic drugs are common and can potentially impact on quality of life as well as concordance with medication.
OBJECTIVES: To investigate prevalence/incidence rates of anticholinergic side-effects of oral antipsychotic drugs over the medium- and long-term.
METHODS: We included all systematic reviews undertaken by the Cochrane Schizophrenia Group for people who are taking antipsychotic drugs and suffering from schizophrenia or Schizophrenia-like illnesses. The prevalence/ incidence of any anticholinergic side-effects was calculated. Relevant papers from the Cochrane Database were identified in January 2007 and the data was pooled. Side-effect data was grouped into the medium (3-6 months) and long-term ( > 6 months). We calculated simple frequencies, proportions and confidence intervals. We undertook a comparison within the group and generated a Forrest plot of the data.
RESULTS: We identified 177 studies within 54 reviews (N=27328 participants). Anticholinergic side-effects for blurred vision, dry mouth and constipation manifested for antipsychotics ranging from 1 to 40 % over the medium-term and 1 to 41% over long-term respectively. There were no statistical differences beween typicals and atypicals over medium- and long-term.
CONCLUSION: To the best of our knowledge, we have collated the largest amount of data on anticholinergic side-effects for antipsychotics over the medium- and longterm. Anticholinergic side-effects are common over the medium- and long-term. Over the medium- and long-term there were no statistically significant differences between the typicals and atypicals in the main anticholinergic side-effects with one exception. We found that in the long-term, the typical antipsychotics were associated with a significantly higher prevalence of blurred vision.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23016549     DOI: 10.2174/092986712803530476

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.

Authors:  Christoph U Correll; Johan Detraux; Jan De Lepeleire; Marc De Hert
Journal:  World Psychiatry       Date:  2015-06       Impact factor: 49.548

Review 2.  Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.

Authors:  Douglas L Boggs; Jon Carlson; Jose Cortes-Briones; John H Krystal; D Cyril D'Souza
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

3.  Treatment of methamphetamine-induced psychosis: a double-blind randomized controlled trial comparing haloperidol and quetiapine.

Authors:  Viroj Verachai; Warangkana Rukngan; Kachornwan Chawanakrasaesin; Sumnao Nilaban; Somporn Suwanmajo; Rossukon Thanateerabunjong; Jaranit Kaewkungwal; Rasmon Kalayasiri
Journal:  Psychopharmacology (Berl)       Date:  2014-02-18       Impact factor: 4.530

4.  Amisulpride augmentation for clozapine-refractory positive symptoms: additional benefit in reducing hypersialorrhea.

Authors:  Fabiani Bogorni; Frederico Fernandes Moreira; Eduardo Mylius Pimentel; Géder Evandro Motta Grohs; Alexandre Paim Diaz
Journal:  Case Rep Psychiatry       Date:  2015-03-09

5.  Detecting potential adverse reactions of sulpiride in schizophrenic patients by prescription sequence symmetry analysis.

Authors:  Edward Chia-Cheng Lai; Cheng-Yang Hsieh; Yea-Huei Kao Yang; Swu-Jane Lin
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

Review 6.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.